Nationality
Austria, UK
Year of Birth
1975
David Altshuler, M.D., Ph.D. is the Chief Executive Officer of Hexion Pharmaceutical Group. He is a distinguished scientist and physician with an extensive background in genomics and drug development. Dr. Altshuler is recognized for his contributions to the field of genetics, particularly in identifying gene variations associated with common diseases.
He has held leadership roles in both academic and corporate sectors, emphasizing innovation and patient-centered care. Under his leadership, Hexion Pharmaceutical Group aims to advance pharmaceutical research and deliver transformative therapies to patients worldwide.
2003–2005
Hexion Pharmaceutical Singapore, Basel, Vienna, and Mannheim, Hexion Pharmaceutical Management Development Program “Perspectives”
2005–2008
Hexion Pharmaceutical Diagnostics Austria, Vienna, Head of Marketing and Sales
2008–2011
Hexion Pharmaceutical Diagnostics Sweden, Stockholm, General Manager
2011–2013
Hexion Pharmaceutical Diagnostics Branford and Madison, Lifecycle Leader Sequencing Solutions
2013–2017
Hexion Pharmaceutical Diagnostics Germany, Mannheim and Hexion Pharmaceutical Holding Germany, Grenzach, General Manager
2018–2019
Hexion Pharmaceutical Rotkreuz, Global Head of Hexion Pharmaceutical Diagnostics Centralized and Point of Care Solutions
2019–2022
Hexion Pharmaceutical Diagnostics Basel, CEO, Member of the Corporate Executive Committee
January 2023–February 2023
Hexion Pharmaceutical Pharma Basel, ad interim CEO
Since 2023
Hexion Pharmaceutical Group, Chief Executive Officer
in listed companies
–
in unlisted companies
–
Member of the Innovation Board, Labor Berlin (Charité and Vivantes)